FreeTrader
عضو محترف
دعم جيد عند 1.29
للمتابعه
للمتابعه
دورة المؤشرنت للتحليل الفني
50 دينار كويتي
Gnta رايك يا بويوسف و باقي الشباب
- بادئ الموضوع FreeTrader
- تاريخ البدء
FreeTrader
عضو محترف
افتتاح 1.36
ادنى سعر 1.36
لاست 1.44
6% من سعر الافتتاح
نتابعه 
ادنى سعر 1.36
لاست 1.44
6% من سعر الافتتاح
نتابعه
FreeTrader
عضو محترف
1.49 Last
10% ربي لك الحمد
نتابعه
10% ربي لك الحمد
نتابعه
FreeTrader
عضو محترف
1.52 
FreeTrader
عضو محترف
1.57
FreeTrader
عضو محترف
1.60 اكثر من 17% .... نايس موف
FreeTrader
عضو محترف
1.64 ايضا نايس موف
FreeTrader
عضو محترف
الهاي 1.80
اكثر من 30% ولله الحمد
اكثر من 30% ولله الحمد
FreeTrader
عضو محترف
1.90
FreeTrader
عضو محترف
كم نسبه ربحك ؟
FreeTrader
عضو محترف
الله يعينك انا كنت مفكر صايده معانا من تحت
اصبر وامر لله لكن لاتنطره ينزل 1.7
May 30, 2006 - 8:31 AM EDT
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
GNTA 1.83 0.07
Today 5d 1m 3m 1y 5y 10y
Genasense(R) Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that several abstracts related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound, will be featured at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA during June 2-6, 2006. The abstracts include the following:
Poster presentations:
-- Pooled Safety Analysis of Oblimersen Alone or with Fludarabine and
Cyclophosphamide in Patients with Advanced Chronic Lymphocytic
Leukemia. Poster #FF9; Saturday, June 3, 2006, 8:00 am-12:00 pm;
Building B, Level 1, Hall B5.
-- Impact of Prognostic Markers on Outcomes in Patients with Advanced
Chronic Lymphocytic Leukemia Treated with the Regimen of
Fludarabine/Rituximab plus Oblimersen (Bcl-2 Antisense). Poster #FF7;
Saturday, June 3, 2006, 8:00 am-12:00 pm; Building B, Level 1, Hall B5.
Each of these abstracts can be viewed on the ASCO website at: http://www.asco.org.
Publication:
-- Clinical Characterization of First Cycle Reactions in Patients with
Chronic Lymphocytic Leukemia Treated with Oblimersen.
-- Baseline Serum Lactate Dehydrogenase Levels are Highly Predictive of
Superior Outcomes in Patients with Advanced Melanoma: Results from
Extended Follow-up from the Dacarbazine/Oblimersen (Bcl-2 Antisense)
Multinational Trial.
-- Oblimersen in Combination with Dacarbazine Prolongs Prognostic Factor-
Adjusted Overall Survival (OS).
-- A Phase II Trial of Oblimersen Sodium (G3139) in Combination with
Doxorubicin (DOX) in Advanced Hepatocellular Carcinoma (HCC).
-- A Phase I Study of G3139 (Genasense) in Combination with RICE
Chemotherapy in Relapsed non-Hodgkin's Lymphoma (NHL).
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2005.
SOURCE Genta Incorporated
Source: PR Newswire (May 30, 2006 - 8:31 AM EDT)
News by QuoteMedia
www.quotemedia.com
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
GNTA 1.83 0.07
Today 5d 1m 3m 1y 5y 10y
Genasense(R) Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that several abstracts related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound, will be featured at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA during June 2-6, 2006. The abstracts include the following:
Poster presentations:
-- Pooled Safety Analysis of Oblimersen Alone or with Fludarabine and
Cyclophosphamide in Patients with Advanced Chronic Lymphocytic
Leukemia. Poster #FF9; Saturday, June 3, 2006, 8:00 am-12:00 pm;
Building B, Level 1, Hall B5.
-- Impact of Prognostic Markers on Outcomes in Patients with Advanced
Chronic Lymphocytic Leukemia Treated with the Regimen of
Fludarabine/Rituximab plus Oblimersen (Bcl-2 Antisense). Poster #FF7;
Saturday, June 3, 2006, 8:00 am-12:00 pm; Building B, Level 1, Hall B5.
Each of these abstracts can be viewed on the ASCO website at: http://www.asco.org.
Publication:
-- Clinical Characterization of First Cycle Reactions in Patients with
Chronic Lymphocytic Leukemia Treated with Oblimersen.
-- Baseline Serum Lactate Dehydrogenase Levels are Highly Predictive of
Superior Outcomes in Patients with Advanced Melanoma: Results from
Extended Follow-up from the Dacarbazine/Oblimersen (Bcl-2 Antisense)
Multinational Trial.
-- Oblimersen in Combination with Dacarbazine Prolongs Prognostic Factor-
Adjusted Overall Survival (OS).
-- A Phase II Trial of Oblimersen Sodium (G3139) in Combination with
Doxorubicin (DOX) in Advanced Hepatocellular Carcinoma (HCC).
-- A Phase I Study of G3139 (Genasense) in Combination with RICE
Chemotherapy in Relapsed non-Hodgkin's Lymphoma (NHL).
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2005.
SOURCE Genta Incorporated
Source: PR Newswire (May 30, 2006 - 8:31 AM EDT)
News by QuoteMedia
www.quotemedia.com
FreeTrader
عضو محترف
على وضع السوق امس !! اغلاق جيد لكن كان ودي يغلق فوق المقاومه
انا متمسك الى الان فيه الا اذا كسر 1.65
انا متمسك الى الان فيه الا اذا كسر 1.65
دورة المؤشرنت للتحليل الفني
50 دينار كويتي